I will say a little bit about the clinical aspects of this, because I think that they are really important. I will start off by trying to answer your question about respiratory care, and then I will perhaps go on to talk about some of the green theatre programme’s work.What really attracted me to focusing work on inhaler usage in Scotland was that, when we began to look at international data and compare Scotland with demographically similar countries, particularly across Scandinavia, with regard to the utilisation of particular devices and health outcomes, there was certainly evidence of much greater usage of short-acting beta-2 therapy inhalers—which, for those on the committee who are not familiar with the terms, are generally what we call reliever inhalers. In Scotland, there seemed to be a disproportionate use of those inhalers compared with preventer inhalers, which form the absolute bedrock and keystone of ensuring good asthma care over a long period of time.The high usage of short-acting beta-2 agonists, in particular, was leading to significant increases in the amount of emissions; people were going through so many more inhalers because they were not actually using the preventer inhalers. Work that has been led around the country—for example, in Glasgow and so forth—is giving us a better understanding of what has been happening there.I do not think this comes down to simply switching from some of the gas-propellant inhalers to the dry powder inhalers; it is about making sure that we optimise the care of patients. The 2024 British Thoracic Society guidelines set out a slightly different approach to modifying drugs usage and take us down a slightly different route in terms of how we use inhalers to improve asthma care. It is all about taking a holistic approach with a patient to see exactly what works for them, given their stage and current experience of asthma. That is certainly what is being advocated in the Scottish prescribing guidelines on respiratory care. This is not just about blanket switching to dry powder inhalers; it is about optimising the care of patients, with the side benefit of an impact on emissions, too.That is a really important point to underline. Emissions have been falling in, I think, quite a striking way. Indeed, the data that I have suggests an 18 per cent fall in emissions, even from 2022-23 to 2024-25, as a result of some of the work that has been going on. All of that is a benefit.We also have to recognise that other medicines that we are using are having a harmful effect on the environment, none more so than the volatile anaesthetic gases that you would have been used to, Ms Harper, when you worked in theatres. Again, extensive work has been carried out in Scotland on how we make best use of those gases, where their use is appropriate, and we have begun to stop using those that are most harmful, such as desflurane. Through the work of national procurement and engagement with clinical teams, we have seen changes to the whole approach to using those volatile gases.Likewise, we need to examine the broader use across our estate of gases such as nitrous oxide, or Entonox, which is often used as a pain-modifying therapy. We must ensure that we are making best use of the infrastructure that sits round about that, in order to reduce the amount of leakage across the system and to make sure that such gases are being used appropriately. We are beginning to see a great reduction in that respect, too.Therefore, side by side with some of the equipment in theatres being used in a completely different way is the different use of the medicines that support those theatres and, indeed, care across our hospitals, and I am really encouraged by that. It is fair to say that, certainly among the community of people across Europe with whom I am involved, Scotland is seen as a leader in this. In the past couple of years, I have had the pleasure of signing a memorandum of understanding with the regional Government in Galicia, as we choose to work together on these types of approaches to ensure that we embed sustainable care in our healthcare systems.